Freedom of Information – Performance
NHS Lanarkshire publishes information on its performance including:
Treatment of patients:
The number of patients living within the NHS Lanarkshire area who have been treated with MS disease modifying drugs
| Disease Modifying Therapy | As at June 2018 | As at September 2018 |
| Alemtuzimab/Lemtrada | 23 | 23 |
| Aubagio / teriflunamide | 35 | 21 |
| Avonex | 93 | 92 |
| Betaferon | <5 | <5 |
| Fampridine | <5 | <5 |
| Copaxone | 29 | 31 |
| Cladribine | 15 | 19 |
| Fingolomod/Gilenya | 63 | 64 |
| Mitoxantrone | <5 | <5 |
| Plegridy | 39 | 38 |
| Rebif 22 | <5 | <5 |
| Rebif 44 | 14 | 14 |
| Tecfidera | 168 | 176 |
| Teriflunamide | 15 | 16 |
| Tysabri | 41 | 138 |
*<5 the figure in this category is five or fewer.
NHS Lanarkshire is measured against the following key performance indicators:
Scottish Public Service Ombudsman Reports:
Can't find what you are looking for?
If the above information is not what you are looking for you can make a request under the freedom of information legislation.
